45results about How to "Short marking time" patented technology

The invention relates to a <18>O on-line marked protein quantitative analysis platform, and an operation method thereof. The <18>O on-line marked protein quantitative analysis platform is a system integrating protein on-line enzymolysis, <18>O on-line marking and polypeptide separation and detection. The <18>O on-line marked protein quantitative analysis platform comprises an injection pump, a sampling needle, a column oven, an enzyme reactor, a switch valve, a peptide fragment capture column, a liquid phase chromatography pump, a polypeptide separation column and a mass spectrometry detector. A protein sample is firstly loaded to the enzyme reactor through the injection pump to carry out incubation; <18>O marking can be carried out at the same time with enzymolysis; and the <18>O marked peptide fragment after enzymolysis is enriched on-line and transferred into the polypeptide separation column for further separation, and finally is detected by the mass spectrometry detector. The <18>O on-line marked protein quantitative analysis platform integrates the protein on-line enzymolysis, <18>O on-line marking and polypeptide separation.

The invention provides a novel <18>F marked substituted quinazoline compound. The novel <18>F marked substituted quinazoline compound is characterized in that one end of the novel <18>F marked substituted quinazoline compound has a <18>F substituted alkyloxy structure; the other end of the compound has a 6,7-substituted quinazoline structure, and a substituent R1 is positioned in the 4 position of a quinazoline maternal, and is a 2-, 3-, 4-<18>F substituted alkyloxy group; and a substituent R2 is positioned in the 6 position of the quinazoline maternal, and is a methoxyethoxy group, a methoxy group, or a morpholinepropanolato group. The structural formula of the compound is shown as A in the specification. Results of experiments show that the compound has the advantages of good bioactivity, good serum stability, low intake in tissues of the liver and the like, and high enrichment and slow removal rate in tumors, and the marking precursor of the compound has the advantages of easy synthesis, extremely high marking rate and the like, so the compound has a huge potential for the tumor PET development.

The invention provides a method for controlling the hydrophilic modification effect inside a micro-fluidic chip, and belongs to the technical field of micro-fluidic chip hydrophilic control. The method is based on the specific and selective recognition effects of aggregation induction luminescent molecules modified by two boric acid groups and PVA containing hydroxyls, the fluorescence visual imaging labeling is performed inside the micro-fluidic chip subjected to hydrophilic treatment; the inside fluorescence intensity and distribution condition can be subjected to measurement and control condition analysis through a fluorescence microscope or a laser co-focusing microscope. The method has the advantages that the in-situ visual control on the micro pore passages in the micro-fluidic chipis realized; the problem that the in-situ detection cannot be realized on the inside of the chip in the conventional measurement can be solved; the method belongs to a safe, nondestructive, fast and effective visual recognition method, and can be widely applied to the materials to realize the fast screening on the hydrophilic treatment effects.

The invention discloses a preparation method of a gold immunochromatography assay test strip indirectly connecting colloidal gold using a goat-anti-mouse secondary antibody with an anti-mouse marker.The preparation method comprises the following steps: (1) preparing a colloidal gold solution by using trisodium citrate to reduce chloroauric acid; (2) using the colloidal gold solution to mark the goat-anti-mouse secondary antibody; (3) adding the to-be-marked mouse antibody into the colloidal gold solution marking the goat-anti-mouse secondary antibody; (4) processing the indirectly marked mouse antibody colloidal gold solution onto a conjugate pad; (5) processing a corresponding antigen onto a nitric acid cellulose membrane; (6) adhering the nitric acid cellulose membrane, water absorptionpaper, the conjugate pad and a sample pad to a PVC plastic bottom plate; and (7) identifying the quality of the prepared gold immunochromatogrpahy assay test strip according to the product quality standard. The preparation method has the advantages that the detection sensitivity of the gold immunochromatogrpahy assay test strip can be improved, the consumption of antibodies used by the marker canbe reduced, the cost is reduced, the performance of the test paper is improved, and the detection result is stable and reliable.

The present invention relates to carbazole fluorescent thymine drug labeling reagent, synthesis and application. Carbazole is used as fluorescent mother ring, benzyl chloride is used as reactive group, and its chemical name is: 4-(9H-carbazole-9- base) benzyl chloride. The novel stable carbazole-based fluorescent thymine drug labeling reagent described in the present invention can accurately, sensitively and rapidly label thymine drugs under mild conditions, thereby realizing the separation of micro and trace amounts of thymine drugs in complex systems It can be used in research fields such as environmental analysis and food safety, and has broad application prospects.

The invention discloses 18F-E[c(RGDyk)2], a medicine box used for automatic production thereof, and a preparation method and use of the medicine box, relates to a polyethylene terephthalate (PET) developer and a preparation method and use thereof and relates to the technical field of radiative medicines and nuclear medicines. The medicine box contains a raw material reagent A and a raw material reagent B. A bottle A contains E[c(RGDyk)2]-NO2; and A bottle B contains acetonitrile solution of crown ether K222 / K2CO3. The 18F-E[c(RGDyk)2] prepared by the medicine box has high absorbing performance and excellent retaining performance in model mouse tumor, and has a very high target / non target ratio, excellent pharmacokinetic characteristic and high biological performance, and can completely meet the requirements of PET developer of tumour integrin alphavbeta3 receptor.